Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus Gemcitabine in Chinese Patients with Metastatic Pancreatic Cancer
NCT02017015Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Celgene Corporation. Started Dec 2013; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02017015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017015.